Quarterly report · Q3
4543.TEDINET S100SSIE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥683.0bn | 2023-04-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥239.1bn | 2023-10-01 → 2023-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥618.0bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥214.7bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥105.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥39.0bn | 2023-10-01 → 2023-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥93.5bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥105.7bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥39.3bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥92.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥79.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.8bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥79.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.8bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥1.69T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.54T | at 2022-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥475.7bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.22T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.07T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.22T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.07T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥163.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥162.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥91.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥74.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥53.1bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥41.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥68.7bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥84.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥107.33 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥40.06 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥93.25 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥107.29 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥40.05 | 2023-10-01 → 2023-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.21 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥39.96 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 71.9% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.6% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-12-31 | ¥172m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥2.1bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥127.8bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥13.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥407.7bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥92.0bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥147.3bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥16.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥682.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥121.9bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-12-31 | ¥186m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥479m |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥113.4bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥358.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥83.6bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥145.5bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥617.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥109.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 653
| Item | Context | Value | Unit |
|---|---|---|---|
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)テルモ株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都渋谷区幡ケ谷二丁目44番１号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of financial position IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of profit or loss IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarter period consolidated statement of profit or loss IFRS (text) | CurrentQuarterDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of comprehensive income IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarter period consolidated statement of comprehensive income IFRS (text) | CurrentQuarterDuration | Text · Plus | |
| Condensed quarterly consolidated statement of changes in equity IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of cash flows IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes reporting entity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes basis of preparation condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting policies condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes share capital and other equity items condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes impairment of non financial assets condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes dividends condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes fair value of financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes contingent liabilities condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |